4C Medical Technologies, Inc.

4C Medical Technologies, Inc. is a privately held medical technology company specializing in minimally invasive therapies for structural heart disease. Their primary focus is the development of the AltaValve™, a novel transcatheter mitral valve replacement (TMVR) device designed to treat mitral regurgitation (MR). The AltaValve™ offers a unique supra-annular approach, positioning the device above the native mitral valve, allowing for a broader treatable patient population, streamlined procedures, and preservation of critical cardiac structures.

The company boasts a strong leadership team with extensive experience in the cardiovascular space, including experts in product design, development, clinical research, and commercialization. 4C Medical has secured significant funding through multiple financing rounds, demonstrating investor confidence in their innovative technology and promising future.

4C Medical Technologies is a privately-held medical technology company dedicated to developing minimally invasive therapies for structural heart disease. The company focuses on redefining solutions for mitral regurgitation, a common heart valve disease affecting millions of people worldwide. They have developed AltaValve™, a novel transcatheter mitral valve replacement (TMVR) device that aims to expand the treatable patient population, streamline the procedure, and preserve critical cardiac structures.

4C Medical Technologies fosters a collaborative and innovative culture driven by a passion for improving patient outcomes in structural heart disease. With a focus on developing minimally invasive therapies, the company values teamwork, dedication, and a drive to push the boundaries of medical technology. The team, comprised of experts in various fields, emphasizes research, development, and clinical excellence while maintaining a commitment to ethical practices and regulatory compliance.